Alta Capital Management LLC Cuts Position in Zoetis Inc. $ZTS

Alta Capital Management LLC decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 93.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,153 shares of the company’s stock after selling 152,485 shares during the quarter. Alta Capital Management LLC’s holdings in Zoetis were worth $1,277,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Zoetis by 12.9% in the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after acquiring an additional 5,474,210 shares in the last quarter. Nordea Investment Management AB raised its position in Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after acquiring an additional 2,179,578 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in Zoetis by 14.6% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock worth $631,046,000 after acquiring an additional 550,859 shares in the last quarter. Alliancebernstein L.P. raised its position in Zoetis by 13.3% in the third quarter. Alliancebernstein L.P. now owns 4,241,357 shares of the company’s stock worth $620,595,000 after acquiring an additional 496,320 shares in the last quarter. Finally, Fundsmith LLP grew its holdings in Zoetis by 25.3% in the third quarter. Fundsmith LLP now owns 3,615,131 shares of the company’s stock valued at $528,966,000 after purchasing an additional 730,300 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 4.8%

ZTS opened at $77.78 on Tuesday. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The firm has a market cap of $32.61 billion, a P/E ratio of 12.90, a PEG ratio of 1.21 and a beta of 0.87. Zoetis Inc. has a 52 week low of $72.38 and a 52 week high of $172.23. The business’s fifty day simple moving average is $111.39 and its 200 day simple moving average is $120.28.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm’s revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities research analysts anticipate that Zoetis Inc. will post 6.91 EPS for the current fiscal year.

Insider Activity at Zoetis

In related news, Director Paul Bisaro acquired 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Frank A. Damelio purchased 6,650 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was acquired at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the purchase, the director owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 11,650 shares of company stock valued at $886,384 over the last quarter. Insiders own 0.22% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ZTS shares. Piper Sandler reissued a “neutral” rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. JPMorgan Chase & Co. lowered their target price on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Finally, UBS Group lowered their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $134.75.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.